Orthofix Medical (OFIX) EBITDA (2010 - 2026)

Orthofix Medical (OFIX) has 17 years of EBITDA data on file, last reported at $17.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 134.53% year-over-year to $17.7 million; the trailing twelve-month figure through Mar 2026 stood at $117.1 million (up 146.03% YoY), and the FY2025 full-year result was $118.9 million, up 192.13% from the prior year.
• EBITDA for Q1 2026 stood at $17.7 million, down from $37.9 million in the prior quarter.
• Across five years, EBITDA topped out at $85.8 million in Q4 2022 and bottomed at -$210.5 million in Q4 2023.
• A 5-year average of -$20.3 million and a median of $7.1 million in 2022 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 2444.94% in 2023, while the deepest fall reached 951.15% in 2023.
• Tracing OFIX's EBITDA over 5 years: stood at $85.8 million in 2022, then slumped by 345.35% to -$210.5 million in 2023, then advanced by 2.47% to -$205.3 million in 2024, then surged by 118.46% to $37.9 million in 2025, then plunged by 53.23% to $17.7 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $17.7 million, $37.9 million, and $32.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison